RAF1 and cholangiocarcinoma: This is in contrast to previous studies with c-MET inhibitors46–48 in which high expression of p-AKT, AKT, p-raf, c-raf, p-ERK, and ERK after 24 h of exposure to Tivantinib was observed and confirmed in CC cell lines, the pancreatic cancer cell line Capan-1, and the hepatocellular carcinoma cell line Huh7.